A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome

BACKGROUND Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a primary immunodeficiency disorder caused by heterozygous gain-of-function CXCR4 mutations. Myelokathexis is a kind of neutropenia caused by neutrophil retention in bone marrow and in WHIM syndrome is associat...

Descripción completa

Detalles Bibliográficos
Autores principales: David H. McDermott, Daniel Velez, Elena Cho, Edward W. Cowen, John J. DiGiovanna, Diana V. Pastrana, Christopher B. Buck, Katherine R. Calvo, Pamela J. Gardner, Sergio D. Rosenzweig, Pamela Stratton, Melissa A. Merideth, H. Jeffrey Kim, Carmen Brewer, James D. Katz, Douglas B. Kuhns, Harry L. Malech, Dean Follmann, Michael P. Fay, Philip M. Murphy
Formato: Artículo
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023-10-01
Colección:The Journal of Clinical Investigation
Materias:
Clinical trials
Immunology
Acceso en línea:https://doi.org/10.1172/JCI164918

Internet

https://doi.org/10.1172/JCI164918

Ejemplares similares